1.
|
Rautava J, Luukkaa M, Heikinheimo K, Alin
J, Grenman R and Happonen RP: Squamous cell carcinomas arising from
different types of oral epithelia differ in their tumor and patient
characteristics and survival. Oral Oncol. 43:911–919. 2007.
View Article : Google Scholar
|
2.
|
Funk GF, Karnell LH, Robinson RA, Zhen WK,
Trask DK and Hoffman HT: Presentation, treatment, and outcome of
oral cavity cancer: a national cancer data base report. Head Neck.
24:165–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Mehrotra R, Singh MK, Pandya S and Singh
M: The use of an oral brush biopsy without computer - assisted
anaylsis in the oral lesions: a study of 94 patients. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 106:246–253. 2008.
View Article : Google Scholar : PubMed/NCBI
|
4.
|
Lawoyin JO, Lawoyin DO and Aderinokun G:
Intra-oral squamous cell carcinoma in Ibadan: a review of 90 cases.
Afr J Med Med Sci. 26:187–188. 1997.PubMed/NCBI
|
5.
|
Chaudhuri NK, Montag BJ and Heidelberger
C: Studies on fluorinated pyrimidines. III The metabolism of
5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer
Res. 18:318–328. 1958.PubMed/NCBI
|
6.
|
Greenburg G and Hay ED: Epithelia
suspended in collagen gels can lose polarity and express
characteristics of migrating mesenchymal cells. J Cell Biol.
95:333–339. 1982. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxali-platin resistance induces epithelial-to-mesenchymal
transition in colorectal cancer cell lines. Clin Cancer Res.
12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar
|
10.
|
Thiery JP and Chopin D: Epithelial cell
plasticity in development and tumor progression. Cancer Metastasis
Rev. 18:31–42. 1999. View Article : Google Scholar
|
11.
|
Kong B, Michalski CW and Kleeff J: Tumor
initiating cells in pancreatic cancer: A critical view. World J
Stem Cells. 1:8–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
13.
|
Lee JH, Kim MC, Oh SY, Kwon HC, Kim SH,
Kwon KA, Lee S, Jeong JS, Choi SR and Kim HJ: Predictive value of
in vitro adenosine triphosphate-based chemotherapy response assay
in advanced gastric cancer patients who received oral
5-fluoro-uracil after curative resection. Cancer Res Treat.
43:117–123. 2011. View Article : Google Scholar
|
14.
|
Gamelin EC, Danquechin-Dorval EM, Dumesnil
YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH,
Gesta PH and Larra FG: Relationship between 5-fluorouracil (5-FU)
dose intensity and therapeutic response in patients with advanced
colorectal cancer receiving infusional therapy containing 5-FU.
Cancer. 77:441–451. 1996. View Article : Google Scholar
|
15.
|
Murakami Y, Uemura K, Sudo T, Hayashidani
Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine
plus S-1 chemotherapy after surgical resection for adenocarcinoma
of the body or tail of the pancreas. J Gastrointest Surg. 13:85–92.
2009. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Huang CL, Yokomise H, Kobayashi S,
Fukushima M, Hitomi S and Wada H: Intratumoral expression of
thymidylate synthase and dihydropyrimidine dehydrogenase in
non-small cell lung cancer patients treated with 5-FU-based
chemotherapy. Int J Oncol. 17:47–54. 2000.
|
17.
|
Furusaka T, Asakawa T, Tanaka A, Matsuda H
and Ikeda M: Efficacy of multidrug superselective intra-arterial
chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the
Seldinger technique for tongue cancer. Acta Otolaryngol.
132:1108–1114. 2012. View Article : Google Scholar
|
18.
|
Lorch JH, Goloubeva O, Haddad RI, Cullen
K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE and Posner
MR; TAX 324 Study Group: Induction chemotherapy with cisplatin and
fluorouracil alone or in combination with docetaxel in locally
advanced squamous-cell cancer of the head and neck: long-term
results of the TAX 324 randomised phase 3 trial. Lancet Oncol.
12:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Blanchard P, Bourhis J, Lacas B, Posner
MR, Vermorken JB, Hernandez JJ, Bourredjem A, Calais G, Paccagnella
A, Hitt R and Pignon JP; Meta-Analysis of Chemotherapy in Head and
Neck Cancer, Induction Project, Collaborative Group:
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally
advanced head and neck cancers: an individual patient data
meta-analysis of the meta-analysis of chemotherapy in head and neck
cancer group. J Clin Oncol. 31:2854–2860. 2013. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Peters GJ, Backus HH, Freemantle S, van
Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J,
Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van
Groeningen CJ and Pinedo HM: Induction of thymidylate synthase as a
5-fluorouracil resistance mechanism. Biochim Biophys Acta.
1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
22.
|
Harada K, Kawashima Y, Yoshida H and Sato
M: Thymidylate synthase expression in oral squamous cell carcinoma
predicts response to S-1. Oncol Rep. 15:1417–1423. 2006.PubMed/NCBI
|
23.
|
Johnston PG, Drake JC, Trepel J and
Allegra CJ: Immunological quantitation of thymidylate synthase
using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive
and -resistant human cancer cell lines. Cancer Res. 52:4306–4312.
1992.
|
24.
|
Plasencia C, Rooney PH, Taron M,
Martinez-Balibrea E, McLeod HL and Abad A: Chromosomal imbalance
maps of human 5FU-resistant colorectal cancer cell lines:
implications in the analysis of 5FU-acquired resistance mechanisms.
Int J Oncol. 22:945–953. 2003.
|
25.
|
Tanaka T, Bai T and Toujima S:
Establishment and characterization of monoclonal
5-fluorouracil-resistant cell lines derived from human endometrial
adenocarcinoma. Int J Oncol. 37:731–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Uchibori K, Kasamatsu A, Sunaga M, Yokota
S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa H
and Sato N: Establishment and characterization of two
5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J
Oncol. 40:1005–1010. 2012.PubMed/NCBI
|
27.
|
Nagata M, Nakayama H, Tanaka T, Yoshida R,
Yoshitake Y, Fukuma D, Kawahara K, Nakagawa Y, Ota K, Hiraki A and
Shinohara M: Overexpression of cIAP2 contributes to 5-FU resistance
and a poor prognosis in oral squamous cell carcinoma. Br J Cancer.
105:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
28.
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
29.
|
Pratt S, Shepard RL, Kandasamy RA,
Johnston PA, Perry W III and Dantzig AH: The multidrug resistance
protein 5 (ABCC5) confers resistance to 5-fluorouracil and
transports its mono-phosphorylated metabolites. Mol Cancer Ther.
4:855–863. 2005. View Article : Google Scholar : PubMed/NCBI
|
30.
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|